Bavarian Nordic issues statement on Mpox vaccine delivery and collaboration with African and global stakeholders

COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on its plans to secure vaccine supply to address the current mpox outbreak, which the Africa Centers for Disease Control and Prevention (Africa CDC) declared a Public Health Emergency of Continental Security (PHECS) on August 13, 2024, followed by the World Health Organization (WHO) declaring mpox a Public Health Emergency of International Concern (PHEIC) on August 14, 2024.

“Bavarian Nordic is working closely with all stakeholders to ensure equitable access to our mpox vaccine during the current PHECS and PHEIC. Importantly, we have built a strong partnership with the Africa CDC, both in terms of supply but also by expanding our manufacturing network into Africa. We are also working with the WHO on a regulatory pathway to ensure access to all countries, while simultaneously seeking approval for use in adolescents and conducting clinical studies in Africa to further expand use to children. We stand ready to work with the Africa CDC and the international community to play our part in protecting and saving lives around the world and containing the latest outbreak,” said Paul Chaplin, President & CEO of Bavarian Nordic.